dc.contributor.author |
Krenács, László |
|
dc.contributor.author |
Tóth-Lipták, Judit |
|
dc.contributor.author |
Demeter, Judit |
|
dc.contributor.author |
Piukovics, Klára |
|
dc.contributor.author |
Borbényi, Zita |
|
dc.contributor.author |
Gogolák, Péter |
|
dc.contributor.author |
Sári, Eszter |
|
dc.contributor.author |
Bagdi, E |
|
dc.date.accessioned |
2020-03-27T07:56:12Z |
|
dc.date.available |
2020-03-27T07:56:12Z |
|
dc.date.issued |
2013 |
|
dc.identifier |
84890478404 |
|
dc.identifier.citation |
journalVolume=463;journalIssueNumber=6;journalTitle=VIRCHOWS ARCHIV;pagerange=787-794;journalAbbreviatedTitle=VIRCHOWS ARCH; |
|
dc.identifier.uri |
http://repo.lib.semmelweis.hu//handle/123456789/7152 |
|
dc.identifier.uri |
doi:10.1007/s00428-013-1490-5 |
|
dc.description.abstract |
The Hector Battifora mesothelial epitope-1 (HBME-1) monoclonal antibody has been generated against human mesothelioma cells and recognizes a biochemically unknown membrane epitope. We have accidentally found that the HBME-1 reacts with scattered lymphocytes showing villous surface in hyperplastic lymphoid tissue. To evaluate its reactivity pattern, we have performed a consecutive immunohistochemical study in nonneoplastic bone marrow and lymphoid samples (n = 40), as well as in malignant lymphoproliferations (n = 427), including hairy cell leukemia (HCL) (n = 72), HCL variant (HCL-v) (n = 13), splenic diffuse red pulp small B cell lymphoma (SDRPL) (n = 8), splenic B cell marginal zone lymphoma (SMZL) (n = 59), and splenic B cell lymphoma/leukemia, not further classifiable on bone marrow morphology (SBCL) (n = 37) cases. The staining pattern of HBME-1 was compared to DBA.44. HBME-1+ villous lymphocytes were constantly detected in low number in nonneoplastic lymphoid tissues. With multicolor immunofluorescence staining, HBME-1+ lymphocytes showed a CD20+/CD79a+/IgM+ B cell phenotype. In B cell lymphoproliferations of villous lymphocytes, HBME-1 reactivity was demonstrated in 96 % of HCL, 39 % of HCL-v, 50 % of SDRPL, 12 % of SMZL, and 19 % of SBCL cases. Nodal and extranodal marginal zone lymphoma cases were positive in 12 % of the cases. A small minority (4 %) of the other B cell lymphomas and no T cell lymphoma revealed tumor cell reactivity with HBME-1. In conclusion, our study has established that HBME-1 reacts with a minor subset of B lymphocytes and a small proportion of B cell lymphomas, which has not been described previously. We suggest that HBME-1 can be a useful marker in the diagnosis of HCL and other indolent lymphoproliferations of villous B lymphocytes. |
|
dc.format.extent |
787-794 |
|
dc.relation.ispartof |
urn:issn:0945-6317 1432-2307 |
|
dc.title |
Monoclonal antibody HBME-1 reacts with a minor subset of B cells with villous surface and can be useful in the diagnosis of hairy cell leukemia and other indolent lymphoproliferations of villous B lymphocytes. |
|
dc.type |
Journal Article |
|
dc.date.updated |
2019-07-05T09:13:00Z |
|
dc.language.rfc3066 |
en |
|
dc.identifier.mtmt |
2446544 |
|
dc.identifier.wos |
000328214900007 |
|
dc.identifier.scopus |
84890478404 |
|
dc.identifier.pubmed |
24092261 |
|
dc.contributor.department |
SE/AOK/K/I. Sz. Belgyógyászati Klinika |
|
dc.contributor.institution |
Semmelweis Egyetem |
|